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Quantiﬁcation of hepatitis B virus (HBV) DNA and quantitative hepatitis B surface antigen (HBsAg) have
improved our understanding and management of chronic hepatitis B (CHB). Both HBV DNA and HBsAg
levels are highest in the immune tolerance phase, start to decline during the immune clearance phase,
and further decline after hepatitis B e antigen (HBeAg) seroconversion. These levels are lowest in the
inactive carrier state but rise again in patients who develop HBeAg-negative hepatitis. Previous studies
have shown that an HBV DNA level 2000 IU/mL is associated with high risks of hepatocellular carci-
noma, liver cirrhosis, and hepatitis activity, whereas a lower HBV DNA level is associated with a better
chance of HBsAg loss, which is very close to a clinical cure for HBV infection. Recent studies further
suggested that HBsAg level is not only a better predictor of HBsAg loss compared with the HBV DNA level,
but also can complement the HBV DNA level in predicting HBV-related adverse events in patients with an
HBV DNA level <2000 IU/mL. In the Asia Paciﬁc region, where HBV genotypes B and C prevail, an HBsAg
level 100 IU/mL has been shown to serve as a predictor of HBsAg loss over time. In HBeAg-negative
patients with an HBV DNA level <2000 IU/mL, an HBsAg level >1000 IU/mL is associated with higher
risks of hepatocellular carcinoma, cirrhosis, and HBeAg-negative hepatitis. European studies also indi-
cated that combining levels of HBsAg <1000 IU/mL and HBV-DNA <2000 IU/mL aids in identifying true
inactive carriers in genotype D HBeAg-negative carriers. All this evidence highlights the evolution of viral
biomarkers in predicting the prognosis of CHB. Quantitative HBsAg can complement HBV DNA in opti-
mizing the management of CHB patients in clinical practice.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Although safe and effective vaccines have been available for
three decades, hepatitis B virus (HBV) infection remains a major
public health problem across the world. The clinical manifestations
of HBV infection range from acute or fulminant hepatitis to various
forms of chronic infection, including the inactive carrier state,
chronic hepatitis, cirrhosis, and even hepatocellular carcinoma
(HCC) [1,2].al Medicine, National Taiwan
outh Road, Taipei, Taiwan.
.
ddhist Compassion Relief Tzu ChiHepatitis B surface antigen (HBsAg) is the hallmark of HBV
infection and was ﬁrst discovered by Blumberg et al in 1965 [3].
Since then, the qualitative status of HBsAg has been used to
deﬁne the HBV infection status. Initially, this marker was not
widely used to monitor disease progression in patients with
chronic HBV infection. In short, clinical practice has generally
relied on qualitative or semiquantitative serological markers, such
as HBsAg and the hepatitis B e antigen (HBeAg), to determine HBV
disease stages. HBsAg is a marker of chronic HBV infection. HBeAg
is a circulating peptide derived from the core gene, then modiﬁed
and secreted from liver cells. It usually serves as a marker of
active viral replication. In addition, liver biochemical markers,
such as the alanine aminotransferase (ALT) level, are checked
repeatedly to evaluate the severity of liver cell necrosis and to
estimate viral activity.Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
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serum HBV DNA level was found to be useful in predicting long-
term adverse outcomes [4,5]. Since then, the HBV DNA level has
been widely used to evaluate viral activity and the risk of disease
progression. The HBV DNA is a more precise predictor of viral ac-
tivity than the ALT level, but both share the same ﬂawdthey vary
with time [6]. Therefore, both require repeated testing to determine
viral activity.
Recently, HBsAg quantiﬁcation has gained much attention
because it stratiﬁes the risk of disease progression more accurately
than HBV DNA level and may serve as a marker reﬂecting host
immune control over HBV infection [7].
In this review article, the evolutionary role of the HBV DNA and
HBsAg levels in predicting the prognosis of chronic hepatitis B
(CHB) is summarized and discussed.
2. Life cycle of HBV and synthesis of HBV DNA and HBsAg
With only 3200 bp in its genome, HBV is the smallest DNA virus.
Fig. 1 illustrates the pathway of HBV DNA and HBsAg production in
the HBV life cycle. The replication template of HBV is the covalently
closed circular DNA (cccDNA), which exists in the liver and encodes
four overlapping open reading frames (ORF).
S stands for the surface or envelope gene, C for the core gene, P
for the polymerase gene, and X for the X gene [2]. The S and C genes
have upstream regions designated pre-S and pre-C. The complete
infectious virion, or Dane particle, is a 42-nm sphere containing the
nucleocapsid and partially double-stranded circular HBV DNA. HBV
DNA is synthesized via reverse transcription of the pregenomic
RNA, which is also derived from cccDNA. Therefore, cccDNA is the
template for both HBV DNA and HBsAg synthesis, although both
products are derived from different ORFs of cccDNA (Fig. 1).
HBsAg is a glycosylated envelope protein of the HBV virion.
There are three HBsAg proteinsdsmall, medium, and largedand
these are produced from three ORFs, called the pre-S1, pre-S2, and S
ORF, of cccDNA. In addition to being on the mature virion, there areFig. 1. Pathway of HBsAg production in the life cycle of HBV replication (adapted from J Gast
B surface Antigen; HBV ¼ hepatitis B virus.large numbers of two types of noninfectious HBsAg particles in the
sera of HBV carriers, spherical particles and ﬁlamentous forms
(Fig. 1). These subviral particles do not contain the HBV genome but
are secreted at levels in excess (100- to 100,000-fold) of mature
virions. In addition, HBsAg can also be derived fromviral sequences
that are randomly integrated into the host genome. Therefore,
whereas serum HBV DNA levels merely reﬂect viral replication
activity, serum HBsAg levels reﬂect activity from translated
messenger RNAs of transcriptionally active cccDNA and from inte-
grated HBV DNA sequences. Thus, the HBsAg level provides com-
plementary information that may improve our understanding of
the infection status of patients.
3. Natural history of CHB
In Asia, where HBV infection is hyperendemic, HBV carriers
usually acquire the virus perinatally or in early childhood (by the
age of 2 years) [8]. Therefore, the age of a given patient can be
considered the duration of HBV infection.
Considering virus and host interaction, the natural course of
chronic HBV infection in Asian patients can be divided into four
chronological phases [9,10] (Fig. 2). The ﬁrst is the “immune
tolerance phase”, where there is active replication of HBV. Hence,
this is characterized by positive HBeAg and normal-to-low ALT
levels. The second is the “immune clearance phase”, where HBeAg-
positive patients have raised ALT and declining HBV DNA levels. In
the third “low replication or residual phase”, where HBeAg is lost,
anti-HBe is gained, and remission of liver disease occurs, and thus
patients are said to be in an “inactive carrier state”. Taken together,
HBeAg seroconversion is regarded as a pivotal event in the natural
history of HBV infection because it usually confers a favorable
clinical outcome [11]. About 20e30% of inactive carriers enter the
“reactivation or HBeAg-negative hepatitis phase”, which is a variant
form of the immune clearance phase [12e14]. Previous longitudinal
studies indicated that HBeAg-negative hepatitis (ENH) is an
important risk factor for subsequent cirrhosis and HCCroenterol. 2013;48:13e21). cccDNA ¼ covalently closed circular DNA; HBsAg ¼ hepatitis
Fig. 2. HBsAg levels in different phases of chronic HBV infection (adapted from J Gastroenterol. 2013;48:13e21). ALT ¼ alanine aminotransferase; HBeAg ¼ hepatitis B e antigen;
HBsAg ¼ hepatitis B surface antigen; HBV ¼ hepatitis B virus.
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at risk of ENH and prompt antiviral treatment are mandatory in
preventing or hindering disease progression. However, ENH also
provides the opportunity for HBsAg seroclearance or seroconver-
sion, which is a favorable clinical outcome [18].
4. HBsAg and HBV DNA levels in different phases of CHB
Several cross-sectional studies have explored HBV DNA and
HBsAg levels in different phases of CHB (Fig. 2) [19e21]. Compa-
rable results have been found irrespective of study population and
HBV genotype. Both HBsAg and HBV DNA levels vary in different
phases of HBV infection but generally decrease as HBV carriers age.
The levels are highest in the initial immune tolerance phase when
there is no or only minimal hepatitis activity and hence, serum ALT
levels are normal. The levels decline during the immune clearance
phase and further decrease in those who maintain normal ALT
levels after HBeAg seroconversion. It has been consistently shown
that the lowest HBsAg and HBV DNA levels occur in the immune
control phase or inactive carrier state but rise again in the reac-
tivation phase or in ENH.
5. Predictive value of HBsAg and HBV DNA in the outcome of
CHB
Several previous studies indicated that in HBV carriers, cirrhosis
is a consequence of extracellular matrix accumulation from liver
cell injury, and HCC may subsequently emerge under this settingTable 1
Summary of three Taiwanese HBV cohort studies.
Cohort Study design Disease stage
REVEAL-HBV Community -based cohort Including HBeAg-positive and -negativ
SEARCH-B Hospital-based cohort Early HBeAg negative phase
ERADICATE-B Hospital-based cohort Including HBeAg-positive and -negativ
ERADICATE-B ¼ Elucidation of Risk fActors for DIsease Control or Advancement in Taiw
REVEAL-HBV ¼ Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Can[15,16]. Therefore, HBV-related hepatitis, cirrhosis, and HCC are
regarded as sequential adverse outcomes. By contrast, HBsAg loss
occurs at an annual rate of 0.5e2.3%, which is a marker for disease
cure [6,22e27]. Fortunately, in the absence of confounding factors,
such as liver cirrhosis, hepatitis C or hepatitis D virus, superinfec-
tion or age >50 years at the time of HBsAg loss, the risk for HCC
development is minimal [28].
Cohort studies are preferred over cross-sectional studies to
investigate the impact of dynamic factors on disease progression, so
we will review the role of HBV DNA and HBsAg levels in predicting
favorable and unfavorable outcomes by referring to three cohort
studies (Table 1). The ﬁrst was a community-based cohort study
known as the Risk Evaluation of Viral Load Elevation and Associated
Liver Disease/Cancer-Hepatitis B Virus (REVEAL-HBV), which fol-
lowed 3653 adult Taiwanese HBsAg seropositive patients over a
mean follow-up period of 11.4 years. The second study was a
hospital-based cohort study, the Study of E Antigen seRoClearance
of Hepatitis B (SEARCH-B). It enrolled 390 Taiwanese spontaneous
HBeAg seroconverters without liver cirrhosis at enrollment and
followed them for an average of 7.4 years. This study is unique in
that it enabled investigation of the early HBeAg-negative stage
because follow-up started at 1 year after HBeAg seroconversion.
The third study was a hospital-based cohort study, the Elucidation
of Risk fActors for DIsease Control or Advancement in Taiwanese
Hepatitis B Carriers (ERADICATE-B), which enrolled 2688 Taiwa-
nese HBV carriers who did not have evidence of cirrhosis at base-
line and were not treated during the follow-up period. The mean
follow-up period was 14.7 years.Number of participants Follow-up (y) References
e phases 3653 11.4 [4,5,26,36,48e50,53,54]
390 7.4 [6,14]
e phases 2688 14.7 [27,47,51]
anese Hepatitis B Carriers; HBeAg ¼ hepatitis B e antigen; HBV ¼ hepatitis B virus;
cer-Hepatitis B Virus; SEARCH-B ¼ Study of E Antigen seRoClearance of Hepatitis B.
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Spontaneous clearance of HBsAg has beenwidely accepted as an
indicator of disease remission [18,28e31]. Earlier studies suggested
that the rate of HBsAg loss is lowest in HBeAg-positive patients,
followed by patients with ENH, and is highest in inactive carriers
[18]. A Taiwanese longitudinal study of 1965 HBeAg-negative pa-
tients with normal ALT levels reported an annual HBsAg loss rate of
1.15% [23]. The authors noted that HBeAg-negative patients with
sustained normal ALT levels were more likely to clear HBsAg than
those with hepatitis relapse. Later, the REVEAL-HBV study found
that a low HBV DNA level could predict HBsAg loss [26], where
patients with an undetectable viral load (<60 IU/mL) had an annual
HBsAg loss rate of 5.76%. Compared with patients with HBV DNA
levels 200,000 IU/mL, the hazard ratio (HR) for HBsAg loss was
15.9 [95% conﬁdence interval (CI), 9.3e27.2]. The positive associa-
tion between limited viral replication and a higher chance of HBsAg
loss as well as a low viral load linked to a low risk of hepatitis
relapse can explainwhy HBsAg clearance occurs more frequently in
patients with persistently normal ALT levels. In addition, the fact
that an undetectable HBV DNA level usually precedes HBsAg loss
also stresses the importance of the HBV DNA level in predicting
HBsAg loss [26].
The SEARCH-B study revealed another predictor for HBsAg loss,
the HBsAg level [6]. In this study, 18 patients cleared HBsAg at an
annual rate of 0.6% during a mean follow-up period of 7.4 years. It
was noted that both lower HBV DNA and HBsAg levels were
associated with a higher likelihood of HBsAg clearance. Evaluation
of 6-year HBsAg loss via receiver operating characteristic (ROC)
curve analysis showed the HBsAg level was a better predictor than
the HBV DNA level (area under the ROC curve: 0.90 vs. 0.69,
p ¼ 0.012). Even in patients with limited viral replication (HBV
DNA level <200 IU/mL), an HBsAg level <100 IU/mL remained an
independent predictor for HBsAg loss. Although this study shed
much light on the importance of HBsAg levels, it lacked the sta-
tistical power to fully establish a relationship between HBsAg
levels and HBsAg loss.
The subsequent ERADICATE-B cohort study investigating the
relationship between HBsAg loss and both HBV DNA and HBsAg
levels in 688 HBeAg-negative patients with HBV DNA levels
<2000 IU/mL at baseline showed similar ﬁndings [27]. This study
had adequate statistical power with 130 patients clearing HBsAg at
an annual rate of 1.6% during a mean follow-up of 11.6 years. It also
found that the HBsAg level served as a better predictor for HBsAg
loss than the HBV DNA level. For example, the HBsAg annual
clearance rate was 7% in patients with an HBsAg level <10 IU/mL,
and its HR for HBsAg loss was 13.2 (95% CI, 8.1e21.5) compared
with an HBsAg level 1000 IU/mL. This large-scale study ﬁrmly
established the importance of HBsAg levels at baseline for subse-
quent HBsAg loss.Table 2
Summary of relationship between HBsAg level and HBsAg loss.
Country Study design Disease stage Number
Taiwan Cohort Early HBeAg-negative stage 390
Hong Kong Cohort HBeAg-negative 103
Taiwan Cohort HBeAg-negative with HBV DNA
level <2000 IU/mL
688
Taiwan Case control HBeAg-negative 46e46
Hong Kong Case control HBeAg-negative 203e203
Taiwan Cohort Children 349
Taiwan Cohort Including HBeAg-positive
and -negative
3466
ERADICATE-B ¼ Elucidation of Risk fActors for DIsease Control or Advancement in Taiwan
antigen; HBV¼ hepatitis B virus; REVEAL-HBV¼ Risk Evaluation of Viral Load Elevation an
seRoClearance of Hepatitis B.Several additional studies reafﬁrmed the relationship between
the HBsAg level and HBsAg loss (Table 2). [4,27,32e36] A cohort
study and a case-control study from Hong Kong showed that a
lower HBsAg level was associated with a higher chance of HBsAg
loss, and HBsAg levels of 100 and 200 IU/mL were the recom-
mended cutoffs, respectively [32,33]. Other studies from Taiwan,
including the REVEAL-HBV cohort study, a pediatric cohort study,
and a case-control study, all had similar data [34e36]. In the recent
REVEAL-HBV study, the authors proposed a 5- and 10-year HBsAg
loss predictionmodel by combining the HBV DNA and HBsAg levels,
and this combination indeed improved the prediction power
compared with HBV DNA alone [36]. In summary, multiple lines of
evidence support the notion that the HBsAg level serves as a very
important predictor for HBsAg loss.
7. Role of HBV DNA and HBsAg levels in predicting HCC risk
Although most longitudinal cohort studies consider chronic
hepatitis, cirrhosis, and HCC as sequential complications [12,15e
17], HCC is still regarded as the most deﬁnitive end point for
complications owing to its disastrous prognosis. In 2006, the
REVEAL-HBV study reported that the serum HBV DNA level was a
major determinant for HCC development [4]. They found that in
adult HBV carriers, a higher HBV DNA level was associated with
HCC development in a dose response manner [4]. In addition, the
risk increased at HBV DNA levels 2000 IU/mL and further
increased when the HBV DNA level was 20,000 IU/mL. These
ﬁndings assisted in establishing 2000 IU/mL as the HBV DNA
threshold required for treatment and deﬁning patients with levels
<2000 IU/mL as inactive HBV carriers [37e39]. Several cross-
sectional and longitudinal studies in Taiwan, Hong Kong, and
China reiterated the impact of the HBV DNA level on HCC devel-
opment [40e46].
As HBsAg quantiﬁcation became available, the association be-
tween the HBsAg level and HCC was ﬁrst addressed by the
ERADICATE-B cohort [47]. Initially, it demonstrated that elevated
HBV DNA and HBsAg levels were both positively correlated with
HCC development. When these two biomarkers were compared,
the HBV DNA level was found to be a better predictor of 10- and 15-
year HCC risk in the overall cohort. However, once the study pop-
ulation was restricted to HBeAg-negative patients with HBV DNA
levels <2000 IU/mL, the HBV DNA level had a minimal role in
predicting HCC, whereas HBsAg retained its predictive value. More
speciﬁcally, in HBeAg-negative patients with HBV DNA levels
<2000 IU/mL, the HCC risk increased in patients with an HBsAg
level 1000 IU/mL compared with those with a level <1000 IU/mL
(HR of 5.4; 95% CI, 2.1e14.2). The 10-year cumulative incidence rate
of HCC was 0.2% for HBeAg-negative patients with an HBV DNA
level <2000 IU/mL and an HBsAg level <1000 IU/mL, similar to the
rate of non-HBV and non-HCV infected individuals [48]. Theof participants HBsAg cutoff (IU/mL) Note References
100 SEARCH-B [4]
100 [32]
10 ERADICATE-B
(partial)
[27]
200 [35]
200 [33]
1000 [34]
100 REVEAL-HBV [36]
ese Hepatitis B Carriers; HBeAg ¼ hepatitis B e antigen; HBsAg ¼ hepatitis B surface
d Associated Liver Disease/Cancer-Hepatitis B Virus; SEARCH-B¼ Study of E Antigen
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DNA level, could further stratify HCC risk in HBeAg-negative pa-
tients with an HBV DNA level <2000 IU/mL [49]. This strengthened
the role of the HBsAg level in predicting HCC in HBV carriers with
low viral loads.
8. Role of HBV DNA and HBsAg levels in predicting liver
cirrhosis
It is generally believed that cirrhosis develops with the accu-
mulation of extracellular matrix consequent to liver cell injury, and
HCC may subsequently emerge in the setting of cirrhosis
[10,12,14e17]. Therefore, it was postulated that if a correlation
exists between HCC and HBV DNA as well as HBsAg levels, the
relationship between these two biomarkers and cirrhosis devel-
opment should also hold. In the REVEAL-HBV study, a dosee
response relationship between the HBV DNA level and cirrhosis
development was indeed noted [50], and the risk started to rise
when the HBV DNA level 2000 IU/mL. The SEARCH-B study
subsequently reafﬁrmed the HBV DNA level as a major stimulant of
cirrhosis development [14].
Based on previous ﬁndings, it is logical to extrapolate that a
similar relationship should exist between the HBsAg level and
cirrhosis development in HBV carriers with low viral loads. The
ERADICATE-B cohort study moved on to investigate this issue by
analyzing 1068 HBeAg-negative patients with low viral loads.
The results showed that an HBsAg level 1000 IU/mL was
consistently associated with a higher cirrhosis risk compared
with an HBsAg level <1000 IU/mL (HR 2.2; 95% CI, 1.1e4.2),
suggesting that HBsAg could assist in predicting cirrhosis
development [51].
9. Role of HBV DNA and HBsAg levels in predicting HBeAg-
negative hepatitis
Hepatitis activity is regarded as the ﬁrst step in many HBV-
related complications. However, unlike cirrhosis and HCC, various
deﬁnitions exist and it can spontaneously resolve. Therefore, a
convincing detection of hepatitis occurrence warrants a cohort
study with regular follow-ups and repeated testing of ALT levels.
[12,14,27] This issue can only be adequately addressed by hospital-
based cohorts that use the following criteria for HBeAg-negative
hepatitis: an ALT level 2 of the upper limit of normal plus an
HBV DNA level 2000 IU/mL. These criteria are consistent with the
deﬁnition of clinical relapse in the guidelines of the Asia Paciﬁc
Association for the Study of the Liver [38].
The relationship between the HBV DNA level and ENH was ﬁrst
publicized in the SEARCH-B study [14]. It found that the risk of ENH
increased if the HBV DNA level at 1 year after HBeAg seroconver-
sion was >200 IU/mL. Compared with patients with an HBV DNA
level <200 IU/mL, the HRs were 2.5 (95% CI, 1.4e4.4) for an HBV
DNA level 2000e20,000 IU/mL, 3.8(95% CI, 2.0e7.3) for a level
20,000e200,000 IU/mL, and 6.7 (95% CI, 4.0e11.2) for a level
200,000 IU/mL.
The ERADCIATE-B study also explored the role of the HBsAg
level in predicting ENH in HBeAg-negative patients with low
viral loads. Again, this study used an HBsAg level of 1000 IU/mL
as the cutoff and showed that a higher HBsAg level was associ-
ated with a higher risk of ENH. Compared with patients with an
HBsAg level <1000 IU/mL, an HBsAg level 1000 IU/mL had an
HR of 1.4 (95% CI, 1.1e1.8) [51]. Furthermore, the low viral load
subcohort of the SEARCH-B study yielded consistent ﬁndings
where the risk of ENH was higher for an HBsAg level 1000 IU/mL
compared with an HBsAg level <1000 IU/mL (unpublished
data).10. Role of HBsAg in predicting HBV reactivation
Chronic hepatitis, cirrhosis, and HCC are sequential complica-
tions of CHB. For patients with low viral loads at baseline, the
instigator of these sequential complications is the reactivation of
HBV replication. Brunetto et al [51] ﬁrst investigated whether
serum HBsAg levels contribute to deﬁne inactive carriers in HBeAg-
negative HBV carriers with genotype D infection. They analyzed
209 treatment-naive and asymptomatic carriers in Italy. Deﬁning
“inactive carrier state” as an HBV DNA level <2000 IU/mL plus a
normal ALT, they found that an HBsAg level <1000 IU/mL at
baseline could identify a 3-year inactive state with 94.3% diagnostic
accuracy, 91.1% sensitivity, 95.4% speciﬁcity, an 87.9% positive pre-
dictive value, and 96.7% negative predictive value. In other words, a
lower HBsAg level at baseline can predict 3-year sustained viral
suppression.
The ERADCATE-B study, which included mostly genotype B and
C patients, reported similar ﬁndings. We analyzed the HBV DNA
level in the 3rd year of follow-up in patients with low viral loads and
found that an HBsAg level <1000 IU/mL was associated with a
lower rate of HBV DNA reactivation [51].
11. Conclusions and perspectives
Ample evidence conﬁrms that a combination of HBV DNA and
HBsAg levels can identify HBV carriers with “minimal viral activity.”
These speciﬁc Asian HBV carriers can thus be regarded at “minimal
risk” for cirrhosis and HCC after long-term follow-up if they have
minimal liver ﬁbrosis at enrollment. Whether this deﬁnition could
be extrapolated to HBV carriers with genotypes other than B or C
requires further validation in different populations.
Limited disease activity in HBV carriers has long been described
as an “inactive carrier state” [37,38]. This relies on patients’ main-
taining low levels of ALT and HBV DNA indeﬁnitely, and hence,
repeated testing of these levels, which is very unlikely in routine
daily practice. Snapshot levels of HBV DNA and HBsAg, by contrast,
enable the identiﬁcation of “minimal viral activity,” in which mul-
tiple Asian and European studies have reported to yield outcomes
comparable to “inactive carriers” [47,52]. Physicians may stratify
patients into risk levels based on viral activity, providing themwith
personalized treatment strategies.
From bench to bedside, several issues need to be addressed.
First, the appropriate cutoffs of the HBsAg level need further ex-
amination. Second, most existing data are from Asian studies
examining patients with genotype B or C, and the validity in Eu-
ropean populationsdwhere different genotypes predominate and
the infection is acquired later in lifedneeds to be investigated. We
hope that, as more lines of evidence accumulate, the HBsAg level
can be integrated to improve the risk calculator or nomogram for
HBV carriers and treatment guidelines for CHB [53,54]. Third,
prospective clinical studies aremandatory to conﬁrm the combined
role of HBV DNA and HBsAg for a “minimal viral activity” cutoff and
to predict disease progression.
In HBV carriers, HBsAg loss is the treatment goal. However, this
is very rarely achieved in patients who acquire the infection peri-
natally. Therefore, the antiviral treatment response has been
deﬁned as an HBV DNA level <2000 IU/mL plus HBeAg serocon-
version at 6 months after therapy for HBeAg-positive patients and
an HBV DNA level <2000 IU/mL at 6 months after therapy for
HBeAg-negative patients. In interferon-based therapy, the HBsAg
level during the treatment seems to predict the treatment response
[55e58]. However, surging evidence has shown that clinical relapse
may occur even if the treatment endpoint is achieved [59]. Simi-
larly, several studies have found a high rate of clinical relapse after
achieving treatment endpoints in patients receiving nucleos(t)ide
T.-C. Tseng, J.-H. Kao / Tzu Chi Medical Journal 25 (2013) 75e8180analogue therapy [60,61]. This is compounded by the fact that the
time point of nucleos(t)ide analogue therapy cessation is difﬁcult to
determine because most patients achieve undetectable viral loads
regardless of future outcome. Because the criteria for “minimal viral
activity” has been established in the natural history of HBV, a
combination of the HBV DNA and HBsAg levels may be adopted to
deﬁne new criteria for treatment response.
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